Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine? - Université de Rennes Accéder directement au contenu
Article Dans Une Revue European Journal of Cancer Année : 2020

Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?

Résumé

A vaccine against SARS-CoV-2 might represent the most promising approach to halt durably the current COVID-19 pandemic. We believe that anti-CD20 therapy may jeopardise the efficacy of such a vaccine. This is regrettable because patients receiving anti-CD20 therapy (i.e. those with haematologic malignancies or autoimmune disorders) are particularly at risk of severe COVID-19 and, as such, are the most in need of a vaccine. Here, we review the reasons why anti-CD20 therapy may abrogate or diminish the efficacy of a vaccine against SARS-CoV-2 and we draw physicians' attention towards this potential risk so that it can be considered when evaluating the risk/benefit ratio of anti-CD20 therapy during the current pandemic.

Domaines

Cancer
Fichier principal
Vignette du fichier
S0959804920303506.pdf (150.42 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-02929021 , version 1 (22-08-2022)

Licence

Paternité - Pas d'utilisation commerciale

Identifiants

Citer

Roch Houot, Ronald Levy, Guillaume Cartron, Philippe Armand. Could anti-CD20 therapy jeopardise the efficacy of a SARS-CoV-2 vaccine?. European Journal of Cancer, 2020, 136, pp.4-6. ⟨10.1016/j.ejca.2020.06.017⟩. ⟨hal-02929021⟩
63 Consultations
35 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More